Personalis EBITDA 2018-2023 | PSNL
Personalis ebitda from 2018 to 2023. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Personalis Annual EBITDA
(Millions of US $) |
| 2023 |
$-101 |
| 2022 |
$-107 |
| 2021 |
$-57 |
| 2020 |
$-36 |
| 2019 |
$-18 |
| 2018 |
$-11 |
| 2017 |
$-21 |
Personalis Quarterly EBITDA
(Millions of US $) |
| 2023-12-31 |
$-22 |
| 2023-09-30 |
$-29 |
| 2023-06-30 |
$-23 |
| 2023-03-31 |
$-27 |
| 2022-12-31 |
$-29 |
| 2022-09-30 |
$-25 |
| 2022-06-30 |
$-26 |
| 2022-03-31 |
$-26 |
| 2021-12-31 |
$-18 |
| 2021-09-30 |
$-16 |
| 2021-06-30 |
$-13 |
| 2021-03-31 |
$-10 |
| 2020-12-31 |
$-12 |
| 2020-09-30 |
$-8 |
| 2020-06-30 |
$-8 |
| 2020-03-31 |
$-8 |
| 2019-12-31 |
$-6 |
| 2019-09-30 |
$-5 |
| 2019-06-30 |
$-3 |
| 2019-03-31 |
$-4 |
| 2018-12-31 |
|
| 2018-09-30 |
$-1 |
| 2018-06-30 |
$-4 |
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.064B |
$0.073B |
|
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
|
